NASDAQ:SMTI - Nasdaq - US79957L1008 - Common Stock - Currency: USD
NASDAQ:SMTI (5/16/2025, 8:22:49 PM)
31.5
+0.62 (+2.01%)
The current stock price of SMTI is 31.5 USD. In the past month the price increased by 7.03%. In the past year, price increased by 3.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 29.45 | 44.89B | ||
COO | COOPER COS INC/THE | 21.99 | 16.58B | ||
ALGN | ALIGN TECHNOLOGY INC | 20.18 | 13.78B | ||
SOLV | SOLVENTUM CORP | 12.46 | 12.82B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 27.68 | 5.84B | ||
LNTH | LANTHEUS HOLDINGS INC | 12.27 | 5.56B | ||
BLCO | BAUSCH + LOMB CORP | 24.5 | 4.16B | ||
HAE | HAEMONETICS CORP/MASS | 15.39 | 3.53B | ||
ICUI | ICU MEDICAL INC | 20.26 | 3.48B | ||
XRAY | DENTSPLY SIRONA INC | 9.94 | 3.33B | ||
UFPT | UFP TECHNOLOGIES INC | 31 | 1.95B | ||
NEOG | NEOGEN CORP | 17.39 | 1.43B |
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. The company markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
SANARA MEDTECH INC
1200 Summit Avenue, Suite 414
Fort Worth TEXAS 76102 US
CEO: Ronald T. Nixon
Employees: 108
Phone: 18175292300
The current stock price of SMTI is 31.5 USD. The price increased by 2.01% in the last trading session.
The exchange symbol of SANARA MEDTECH INC is SMTI and it is listed on the Nasdaq exchange.
SMTI stock is listed on the Nasdaq exchange.
8 analysts have analysed SMTI and the average price target is 49.47 USD. This implies a price increase of 57.05% is expected in the next year compared to the current price of 31.5. Check the SANARA MEDTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SANARA MEDTECH INC (SMTI) has a market capitalization of 280.04M USD. This makes SMTI a Micro Cap stock.
SANARA MEDTECH INC (SMTI) currently has 108 employees.
SANARA MEDTECH INC (SMTI) has a support level at 27.02 and a resistance level at 31.88. Check the full technical report for a detailed analysis of SMTI support and resistance levels.
The Revenue of SANARA MEDTECH INC (SMTI) is expected to grow by 21.95% in the next year. Check the estimates tab for more information on the SMTI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SMTI does not pay a dividend.
SANARA MEDTECH INC (SMTI) will report earnings on 2025-08-11.
SANARA MEDTECH INC (SMTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
The outstanding short interest for SANARA MEDTECH INC (SMTI) is 7.03% of its float. Check the ownership tab for more information on the SMTI short interest.
ChartMill assigns a technical rating of 1 / 10 to SMTI. When comparing the yearly performance of all stocks, SMTI is a bad performer in the overall market: 60.34% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SMTI. SMTI has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SMTI reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS decreased by -127.46% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.97% | ||
ROE | -24.53% | ||
Debt/Equity | 0.78 |
ChartMill assigns a Buy % Consensus number of 83% to SMTI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -68.66% and a revenue growth 21.95% for SMTI